multiQure selects Andelyn to manufacture Huntington’s gene therapy
multiQure has selected US contract development and manufacturing organisation (CDMO) Andelyn Biosciences to manufacture its investigational gene therapy MQ-201 for Huntington’s disease, as the programme moves towards first patient administration.
Andelyn will develop and manufacture the plasmids and AAV5 viral vector required for the therapy, with initial work focused on establishing and optimising the manufacturing process.
The partnership marks a step towards producing good manufacturing practice (GMP) material for clinical use, although the first stage will culminate in a research-grade AAV5 vector batch rather than clinical material.
MQ-201 is an RNA interference (RNAi) gene therapy designed to silence the mutant huntingtin (HTT) gene responsible for Huntington’s disease while preserving the normal copy.
AAV5 manufacturing process to be developed
The first phase of the collaboration will use Andelyn’s AAV Curator platform to develop a manufacturing process tailored to MQ-201.
Activities will include establishing a vector titre assay for the therapy’s expression cassette, preparing plasmids and optimising cell culture and purification processes.
The work will culminate in the production of a research-grade AAV5 vector batch using a 50-litre bioreactor.
Andelyn uses suspension HEK293 cell culture for viral vector production. multiQure said the same manufacturing platform will be used for subsequent GMP production, avoiding the need to transfer the process to a different system before clinical manufacturing.
Sławomir Wójcik, member of the management board at multiQure, said: “Selecting a manufacturer changes the nature of our work: from now on, we are preparing a therapy that we intend to administer to the first patients with Huntington’s disease. The viral vector is the most complex and costly part of the path to the clinic, so we were looking for a partner that has already produced hundreds of clinical batches and whose facility has passed an FDA inspection and EU audits.”
The companies have signed an agreement covering the initial manufacturing stage and are finalising a broader framework agreement for subsequent work leading to GMP clinical material.
Huntington’s disease gene therapy programme advances
Andelyn specialises in viral vector development and manufacturing for gene therapies. The company reports more than 20 years of experience and over 500 cGMP batches produced for more than 80 clinical trials.
Its Columbus, Ohio, facility has passed an FDA pre-license inspection and audits by EU Qualified Persons.
Matt Niloff, chief commercial officer at Andelyn Biosciences, said: “We are very pleased that multiQure has chosen Andelyn as its manufacturing partner for MQ-201. Selecting a vector manufacturer is one of the most important decisions in gene therapy development, and for multiQure it marks the start of the decisive phase of preparations for the first administration of the therapy to patients.”
There is currently no approved treatment that slows the progression of Huntington’s disease. The condition is caused by mutations in the HTT gene, which lead to production of an abnormal huntingtin protein and progressive damage to nerve cells.
MQ-201 is designed to selectively silence the mutant copy of HTT, potentially avoiding the effects of reducing production of normal huntingtin protein.
MQ-201 follows a developing gene therapy field
The programme is progressing alongside other gene therapy approaches targeting Huntington’s disease.
The US Food and Drug Administration (FDA) has accepted uniQure’s application for accelerated approval of AMT-130, an AAV5-based gene therapy also designed to silence HTT. The FDA’s target action date for the application is May 1, 2027.
Unlike AMT-130, multiQure says MQ-201 is designed to selectively target the mutant HTT copy while leaving the normal gene intact.
The company has also signed a letter of intent with Bródno Masovian Hospital in Poland and its Interventional Neurotherapy Center regarding experimental administration of the therapy. Granzer Regulatory Consulting & Services is supporting the regulatory pathway, including preparation of an investigational new drug (IND) application.
The appointment of Andelyn establishes a manufacturing partner for the programme, but GMP clinical production and regulatory clearance will be needed before the therapy can progress to patient administration.




